Cargando…
Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
A physiologically based pharmacokinetic (PBPK) model was developed to evaluate and predict (1) the effect of concomitant cytochrome P450 3A (CYP3A) inhibitors or inducers on the exposures of zanubrutinib, (2) the effect of zanubrutinib on the exposures of CYP3A4, CYP2C8, and CYP2B6 substrates, and (...
Autores principales: | Wang, Kun, Yao, Xueting, Zhang, Miao, Liu, Dongyang, Gao, Yuying, Sahasranaman, Srikumar, Ou, Ying C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129716/ https://www.ncbi.nlm.nih.gov/pubmed/33687157 http://dx.doi.org/10.1002/psp4.12605 |
Ejemplares similares
-
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies
por: Ou, Ying C., et al.
Publicado: (2021) -
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
por: Zhang, Heather, et al.
Publicado: (2021) -
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
por: Ou, Ying C., et al.
Publicado: (2021) -
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
por: Mu, Song, et al.
Publicado: (2019) -
Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
por: Mulford, Darcy J., et al.
Publicado: (2023)